DNA Repair data presented at American Academy of Dermatology Meeting
First results of afamelanotide in xeroderma pigmentosum C (XPC) presented to Photodermatology...
Read MorePRÉNUMBRA® Formulation Completed For Clinical Trial Use
CLINUVEL today announced the completion of manufacture of the first cGMP batch...
Read MoreAfamelanotide Significantly Reduces UV Skin Damage in a Healthy Population - Technical Note
Melbourne, Australia, 02 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreCLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
Results released today from a clinical study have shown that the drug...
Read MoreAfamelanotide Significantly Reduces UV Skin Damage in a Healthy Population
Melbourne, Australia, 02 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreMedia release: CLINUVEL Trial Results Show Drug Reduces DNA Damage
Results from a clinical trial in a genetic DNA repair disorder show...
Read MoreAfamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum - Technical Note
Melbourne, Australia, 16 January 2023 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read MoreAfamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum
First Phase II results show decrease in UV-induced skin damage
Read MoreFirst vitiligo patient enrolled in afamelanotide monotherapy study
CUV104 study to evaluate the role of afamelanotide as monotherapy in patients...
Read MoreCLINUVEL submits SCENESSE® label expansion for adolescent EPP patients
European regulatory submission follows clinical support for SCENESSE® treatment in EPP patients...
Read MorePRÉNUMBRA® for stroke
Melbourne, Australia, 28 July 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read MoreCLINUVEL progresses vitiligo treatment program
A new potential therapy for the pigment loss disorder vitiligo will undergo...
Read MorePositive final results in stroke
CLINUVEL today released positive final results of the open label pilot study...
Read MoreCLINUVEL Extends Employment Agreement With CEO
CLINUVEL today announced that it has extended the Employment Agreement with the...
Read MoreDNA Repair Communiqué II
In this DNA Repair Communiqué II we delve deeper into the topic...
Read More